Achondroplasia clinical trials

Explore recruiting achondroplasia clinical trials.

Recruiting achondroplasia studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Achondroplasia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2, Open-Label, Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of BMN 111 in Children with Achondroplasia

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase 2b, Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Preceded by a Single Ascending Dose Portion and a Phase 2 Open-Label Portion, to Evaluate the Safety and Efficacy of Oral Infigratinib in Infants and Young Children with Achondroplasia

Spain, Norway

Therapeutic exploratory (Phase II) EU CTIS Study details

AttaCH: A Phase 2, Multicenter, Long-Term, Open Label Extension Trial Evaluating Safety, Tolerability, and Efficacy of Subcutaneous Doses of TransCon CNP Administered Once Weekly in Children and Adolescents with Achondroplasia

Denmark, Ireland, Austria, Germany, Portugal, Spain +4 more

Therapeutic exploratory (Phase II) EU CTIS Study details

teACH: A Phase 2b, Multicenter, Double-Blind, Randomized, Placebo controlled Trial evaluating Efficacy and Safety of Subcutaneous Doses of Navepegritide Administered Once Weekly for 52 Weeks in Adolescents (12-<18 years of age) with Achondroplasia

Denmark, France, Ireland

Therapeutic exploratory (Phase II) EU CTIS Study details

ApproaCH: A Phase 2b, Multicenter, Double-Blind, Randomized, Placebo-controlled Trial evaluating Efficacy and Safety of Subcutaneous Doses of TransCon CNP Administered Once Weekly for 52 Weeks in Children with Achondroplasia followed by an Open Label Extension period

Ireland, Spain, Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2, open-label, multi-center, 2-stage sequential cohort, dose escalation study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of subcutaneous SAR442501 in pediatric participants with Achondroplasia

Italy, Spain, Czechia

Therapeutic exploratory (Phase II) EU CTIS Study details

Achondroplasia trials by city

Achondroplasia in Toronto Achondroplasia in Vancouver Achondroplasia in Montreal Achondroplasia in Calgary Achondroplasia in Edmonton Achondroplasia in Ottawa Achondroplasia in Winnipeg Achondroplasia in Quebec City Achondroplasia in Hamilton Achondroplasia in Kitchener Achondroplasia in London Achondroplasia in Halifax Achondroplasia in New York Achondroplasia in Los Angeles Achondroplasia in Chicago Achondroplasia in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease